R&D grant from AMED for T-ignite cancer immunotherapy

April 30th, 2021 | Press Release

We have entered into a contract research and development agreement with the Japan Agency for Medical Research and Development (AMED) for a project to develop a nanotechnology-applied cancer immunotherapy as a program of the Creation of Innovative Infrastructure for Clinical Research and Development (CiCLE).

Back to Press releases

We want to provide you with the most important information and services in the best possible way. In order to do this, we need your consent to use the web analysis tool »Google Analytics« to create and evaluate an anonymous analysis of your visit for statistical purposes. You can change your consent at any time on the data protection page, otherwise it will remain valid for twelve months.